SCHEMBL23630324

SCHEMBL23630324

Nc1nnc(Cl)cc1N1CCN(c2ccc(C(=O)O)cn2)CC1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMO Q99835 2/20 0.45
▸ OGA O60502 1/20 0.44
▸ NAPRT Q6XQN6 1/20 0.42
▸ KMT2A Q03164 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ NPC1 O15118 1/20 0.41
▸ HDAC3 O15379 1/20 0.39
▸ HDAC2 Q92769 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ UBE2T Q9NPD8 1/20 0.39
▸ GABRP O00591 1/20 0.39
▸ GABRD O14764 1/20 0.39
▸ GABRA1 P14867 1/20 0.39
▸ GABRB1 P18505 1/20 0.39
▸ GABRG2 P18507 1/20 0.39
▸ GABRB3 P28472 1/20 0.39
▸ GABRA5 P31644 1/20 0.39
▸ GABRA3 P34903 1/20 0.39
▸ GABRA2 P47869 1/20 0.39
▸ GABRB2 P47870 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29944132 0.85 P2RY12 (0.53) OGAKMT2ARAB9ANPC1MEN1
SCHEMBL23630486 0.85 P2RY12 (0.53) OGAKMT2ARAB9ANPC1MEN1
SCHEMBL23630405 0.83 PIK3CA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL29943886 0.83 PIK3CA (0.54) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL23630485 0.77 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL29944092 0.77 ALDH1A1 (0.55) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL23630521 0.76 PRKCQ (0.40) KMT2AMEN1ALDH1A1KDM4EGAA
SCHEMBL29944108 0.74 GABRP (0.45) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL23630379 0.74 GABRP (0.45) GABRPGABRDGABRA1GABRB1GABRG2
SCHEMBL1989630 0.73 UBE2T (0.63) SMOOGANAPRTKMT2ARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230091042-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2023-03-23 — — US disclosed
EP-4087658-A1 SMARCA2-VHL DEGRADERS Amgen Inc. (US) 2022-11-16 — — EP disclosed
WO-2021142247-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2021-07-15 — — WO disclosed
WO-2021142247-A1 SMARCA2-VHL DEGRADERS AMGEN INC. (US) 2021-07-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230091042-A1 SMARCA2-VHL DEGRADERS VHL, SMARCC2, SMARCC1 SMO 1220/4885OGA 2487/4885NAPRT 3236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback